Gugger James J, Wagner Mary L
School of Pharmacy, University of Connecticut, Storrs, CT, USA.
Ann Pharmacother. 2007 Nov;41(11):1833-41. doi: 10.1345/aph.1H587. Epub 2007 Oct 9.
To describe the clinical features of rapid eye movement (REM) sleep behavior disorder (RBD), evaluate treatment options, and discuss management of patients with comorbid diseases.
A MEDLINE search (1977-April 2007) using the terms REM sleep behavior disorder, narcolepsy, parkinsonian disorders, levodopa, dopamine agonists, clonazepam, benzodiazepines, and melatonin was used to retrieve relevant articles. The reference sections of all articles and texts were scanned for additional literature.
All articles published in English were evaluated. There were no specific criteria for inclusion of articles in this review.
RBD is characterized by enactment of dream content resulting from the loss of normal skeletal muscle atonia during REM sleep. RBD occurs mainly in geriatric patients and in patients with neurodegenerative diseases, especially parkinsonian diseases. The presence of idiopathic RBD may be a sign of an underlying parkinsonian syndrome. Development of RBD may be one of the first manifestations of Parkinson's disease or other parkinsonian syndromes. An acute form of RBD can be drug-induced or occur on drug withdrawal. The potential for injury to the patient and his or her bed partner is as high as 96%. Controlled trials are unavailable for most agents used in the treatment of RBD, although clonazepam is an effective first-line agent and can provide rapid and complete symptom remission based on evidence from 3 large case series. Patients who cannot tolerate clonazepam or who have a suboptimal response may benefit from melatonin alone or as an adjunct. Both drugs are generally well tolerated when taken at bedtime. Management of patients with RBD becomes complicated due to the high incidence of neurologic comorbidity.
Clonazepam is the treatment of choice for patients with RBD. The drug is efficacious and has a low incidence of adverse effects. Melatonin is a viable second-line or adjunctive treatment.
描述快速眼动(REM)睡眠行为障碍(RBD)的临床特征,评估治疗选择,并讨论合并其他疾病患者的管理。
使用术语“REM睡眠行为障碍”“发作性睡病”“帕金森病性障碍”“左旋多巴”“多巴胺激动剂”“氯硝西泮”“苯二氮䓬类药物”和“褪黑素”对MEDLINE(1977年 - 2007年4月)进行检索,以获取相关文章。对所有文章和文本的参考文献部分进行扫描以查找其他文献。
评估所有以英文发表的文章。本综述纳入文章没有特定标准。
RBD的特征是在REM睡眠期间因正常骨骼肌失弛缓而出现梦境内容的动作表现。RBD主要发生在老年患者和神经退行性疾病患者中,尤其是帕金森病性疾病患者。特发性RBD的存在可能是潜在帕金森综合征的一个迹象。RBD的发生可能是帕金森病或其他帕金森综合征的首发表现之一。急性形式的RBD可能是药物引起的或在停药时发生。患者及其同床伴侣受伤的可能性高达96%。尽管根据3个大型病例系列的证据,氯硝西泮是一种有效的一线药物,可快速完全缓解症状,但对于大多数用于治疗RBD的药物尚无对照试验。不能耐受氯硝西泮或反应欠佳的患者可能单独使用褪黑素或作为辅助治疗受益。两种药物在睡前服用时一般耐受性良好。由于神经合并症的高发生率,RBD患者的管理变得复杂。
氯硝西泮是RBD患者的首选治疗药物。该药物有效且不良反应发生率低。褪黑素是一种可行的二线或辅助治疗药物。